000			02204 a2200637 4500
005			20250518044735.0
264		0	_c20191024
008			201910s 0 0 eng d
022			_a1095-6859
024	7		_a10.1016/j.ygyno.2019.06.011 _2doi
040			_aNLM _beng _cNLM
100	1		_aTang, Monica
245	0	0	_aPARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. _h[electronic resource]
260			_bGynecologic oncology _c09 2019
300			_a531-538 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnastrozole _xadverse effects
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aCarcinoma, Ovarian Epithelial _xdrug therapy
650	0	4	_aCystadenocarcinoma, Serous _xdrug therapy
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Grading
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPostmenopause
650	0	4	_aProgression-Free Survival
650	0	4	_aProspective Studies
650	0	4	_aQuality of Life
650	0	4	_aReceptors, Estrogen _xmetabolism
650	0	4	_aReceptors, Progesterone _xmetabolism
650	0	4	_aYoung Adult
700	1		_aO'Connell, Rachel L
700	1		_aAmant, Frederic
700	1		_aBeale, Philip
700	1		_aMcNally, Orla
700	1		_aSjoquist, Katrin M
700	1		_aGrant, Peter
700	1		_aDavis, Alison
700	1		_aSykes, Peter
700	1		_aMileshkin, Linda
700	1		_aMoujaber, Tania
700	1		_aKennedy, Catherine J
700	1		_adeFazio, Anna
700	1		_aTan, King
700	1		_aAntill, Yoland
700	1		_aGoh, Jeffrey
700	1		_aBonaventura, Tony
700	1		_aScurry, James
700	1		_aFriedlander, Michael
773	0		_tGynecologic oncology _gvol. 154 _gno. 3 _gp. 531-538
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2019.06.011 _zAvailable from publisher's website
999			_c29824076 _d29824076